Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations


Objective. To prospectively monitor inflammatory activity over a prolonged period in a cohort of Turkish patients with FMF, their healthy relatives and healthy controls and to relate this to their MEFV genotypes.

Methods. 43 patients with FMF and 75 of their asymptomatic relatives underwent fortnightly assessments and venesection for measurement of CRP and SAA over 5 months. 50 unrelated healthy population matched controls were also studied. MEFV genotyping was performed on all participants and comparisons were made between the different groups.

Results. Paired MEFV mutations were detected in 84% of FMF patients and single mutations in 12%. Substantial acute phase reactivity was seen among the patients with FMF during attacks (median SAA 693 mg/l, CRP 115 mg/l). Between attacks there was also some inflammatory activity (median SAA 6 mg/l, CRP 4 mg/l). Among healthy controls 16% were heterozygotes for MEFV mutations and 4% had two mutations. As expected there was a substantial carrier rate among healthy relatives with mutations detected in almost 92%. Asymptomatic MEFV heterozygotes had elevated acute phase proteins compared to wild type subjects.

Conclusion. Substantial sub-clinical inflammation occurs widely and over prolonged periods in patients with FMF, indicating that the relatively infrequent clinically overt attacks represent the ‘tip of the iceberg’ in this disorder. Both basal and peak acute phase protein concentrations were greater in MEFV heterozygotes than in wild-type controls, regardless of mutation demonstrating a ‘pro-inflammatory’ phenotype among FMF carriers. Upregulation of the acute phase response among carriers of FMF may augment their innate host response and contribute to better resistance to infection.

Key words: Familial Mediterranean fever, MEFV, Heterozygote, Carrier state, Acute phase response, CRP, SAA, Turkey.
Patients and methods

The subjects were 168 ethnic Turks living in the western coastal region of Turkey, in an area served by the Dokuz Eylul University School of Medicine, Izmir. The group comprised 43 patients who fulfilled clinical diagnostic criteria for FMF and 75 of their asymptomatic first-degree relatives from 35 families, and 50 unrelated healthy population-matched controls. FMF in all of the patients had been well characterized and they had all been prescribed prophylactic colchicine at doses of 1–1.5 mg depending on body weight. The protocol for the patients and relatives comprised fortnightly home assessments and venesection for estimation of CRP and SAA for 5 months, and keeping diaries throughout the study period to record symptoms referable to FMF and any intercurrent illnesses. The 50 controls were all overtly healthy adults who each provided three serum blood samples at fortnightly intervals. The protocol included MEFV genotyping in all participants. The study was approved by the Dokuz Eylul University School of Medicine ethical committee and all participants provided informed consent before entering the study.

Measurement of CRP and serum amyloid A protein

All analyses were performed at the end of the study period on separated serum, which had been stored at –30°C. Under these conditions the proteins are very stable [28].

Serum CRP concentration was determined using a high-sensitivity (hs) automated microparticle-enhanced latex turbidimetric immunoassay (Cobas Mira; Roche Diagnostics). The lower limit of detection was 0.2 mg/l; the interassay coefficient of variation (CV) was 4.2% at 4 mg/l and 6.3% at 1 mg/l. SAA concentration was measured by latex nephelometry (BNII auto-analysers; Dade Behring, Marburg, Germany) [29]. The lower limit of detection was 0.7 mg/l; the interassay CV was 2.6% at 15 mg/l and 3.7% at 80 mg/l. Both assays were standardized with the appropriate WHO standards [30, 31].

Genomic DNA was isolated by a rapid method from frozen whole blood taken into ethylenediamine tetraacetate (EDTA) and solubilized in 10 mM Tris, pH 7.5/l mM EDTA [32]. The coding regions of the MEFV gene were amplified by the polymerase chain reaction (PCR) using Taq polymerase (Amplitaq; Perkin Elmer Cetus) and sequenced using BigDye® Terminator sequencing chemistry and an ABI 310 sequencing machine as previously described [10].

Results

DNA analysis was unsuccessful in one of the healthy controls. No MEFV mutations were identified in exons 2, 3, 5 or 10 among 39 (80%) of the remaining 49 individuals. However, two of these healthy subjects were found to have pairs of FMF-associated mutations, encoding the variants V726A/E148Q and M694V/E148Q, respectively; these have been reported separately [15]. Eight others (16%) were simple heterozygotes (Table 1).

Among the 43 patients with FMF, paired MEFV mutations were identified in 36 cases (84%). Thirty of these had two mutations in exon 10, including six who were homozygous for M694V, which is reported to be associated with a severe phenotype, and six had an exon 10 mutation in conjunction with the E148Q variant (Table 1). A single mutation was detected in five patients (12%), and no mutations were found in two cases (5%). One of these patients without identified mutations had no evidence

### Table 1. MEFV genotyping in patients with familial Mediterranean fever, their asymptomatic first-degree relatives and healthy Turkish controls

<table>
<thead>
<tr>
<th>MEFV mutation</th>
<th>Clinical FMF (n = 43)</th>
<th>Asymptomatic relatives (n = 73)</th>
<th>Healthy controls (n = 49)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exon 10</td>
<td>Exon 2</td>
<td>No.</td>
<td>%</td>
</tr>
<tr>
<td>V726A</td>
<td>E148Q</td>
<td>2</td>
<td>4.7%</td>
</tr>
<tr>
<td>V726A</td>
<td>E148V</td>
<td>2</td>
<td>4.7%</td>
</tr>
<tr>
<td>M680I</td>
<td>E148Q</td>
<td>2</td>
<td>4.7%</td>
</tr>
<tr>
<td>M680I</td>
<td>M680I</td>
<td>2</td>
<td>4.7%</td>
</tr>
<tr>
<td>M680I/M694V</td>
<td>V726A</td>
<td>4</td>
<td>9.3%</td>
</tr>
<tr>
<td>M680I/V726A</td>
<td>4</td>
<td>9.3%</td>
<td>1</td>
</tr>
<tr>
<td>M694V</td>
<td>E148Q</td>
<td>6</td>
<td>14%</td>
</tr>
<tr>
<td>M694V</td>
<td>E148Q</td>
<td>2</td>
<td>4.7%</td>
</tr>
<tr>
<td>M694V/M694V</td>
<td>V726A</td>
<td>6</td>
<td>14%</td>
</tr>
<tr>
<td>M694V/V726A</td>
<td>7</td>
<td>16.3%</td>
<td>1</td>
</tr>
<tr>
<td>M694V/R761H</td>
<td>2</td>
<td>4.7%</td>
<td>1</td>
</tr>
<tr>
<td>K695R</td>
<td>V726A</td>
<td>1</td>
<td>2.3%</td>
</tr>
<tr>
<td>V726A/V726A</td>
<td>1</td>
<td>2.3%</td>
<td>1</td>
</tr>
<tr>
<td>V726A/R761H</td>
<td>2</td>
<td>4.7%</td>
<td>3</td>
</tr>
<tr>
<td>R761H</td>
<td>E148Q</td>
<td>6</td>
<td>14%</td>
</tr>
<tr>
<td>No mutation identified</td>
<td>2</td>
<td>4.7%</td>
<td>6</td>
</tr>
<tr>
<td>Single mutation</td>
<td>5</td>
<td>11.6%</td>
<td>58</td>
</tr>
<tr>
<td>Two or more mutations</td>
<td>36</td>
<td>83.7%</td>
<td>9</td>
</tr>
<tr>
<td>Two mutations in exon 10</td>
<td>30</td>
<td>69.8%</td>
<td>4</td>
</tr>
</tbody>
</table>
of significant inflammatory activity and no clinical attacks during the study period (hs-CRP, median 1.1 mg/l, maximum 2.6 mg/l); the other had levels of inflammation compatible with FMF patients with confirmed mutations (hs-CRP, median 16.1 mg/l, maximum 100.2 mg/l).

The allele frequency of MEFV mutations among the 73 asymptomatic parents or siblings of patients with FMF was 0.58. Fifty-eight (80%) of these subjects were heterozygotes, and, despite their lack of symptoms, nine (12%) individuals had paired mutations (Table 1).

Serial measurements of the acute-phase reactants SAA and hs-CRP in the 38 asymptomatic individuals who were MEFV wild-type gave values that were within the range reported in healthy control populations, in which 90% values of are less than 3 mg/l. The median SAA value was 2.2 mg/l and the median hs-CRP value was 1.3 mg/l. Occasional spikes of acute-phase activity were recorded in these individuals but only in the presence of reported intercurrent illness, such as upper respiratory tract infections. The maximum recorded values for SAA (277 mg/l) and hs-CRP (24.4 mg/l) occurred during a self-reported attack of ‘influenza’.

By contrast, substantial acute-phase activity was evident among the patients with FMF. Of the 43 patients, 14 (33%) had two or three FMF attacks during the study period, a further 14 had a single attack and 15 patients reported no FMF symptoms, although seven of these individuals reported episodes of mild ‘flu’-like symptoms that they attributed to viral illnesses. Both SAA and hs-CRP were massively elevated during all reported clinical attacks of FMF in all patients, with median values of 693 (range 140–1330) mg/l and 115 (range 26–296) mg/l, respectively. SAA and hs-CRP were also both elevated compared with the healthy control group even when these patients were free of FMF symptoms [median SAA 6.0 (range 0.7–1230) mg/l; median hs-CRP 4.0 (range 2.7–262) mg/l]. Even when the patients were asymptomatic, only 29% of SAA measurements in the FMF patients were less than 3 mg/l, i.e. within the normal range; 65% were less than 10 mg/l and 13% of SAA values exceeded 50 mg/l. Markedly elevated SAA values in eight individuals who reported no FMF or other symptoms are given in Table 2, suggesting a gene dose effect. The up-regulation of SAA and CRP production during health and intercurrent illness observed here over a prolonged time course in characterized MEFV heterozygotes confirms and extends previous observations on the phenotype of FMF carriers [33].

The degree and periodic pattern with which SAA was elevated in patients with FMF is significant for several reasons. Firstly, it may help to point towards this diagnosis, since very few disorders are associated with repeatedly high SAA values of more than 1000 mg/l [34]. Secondly, the SAA concentration was always very significantly elevated during symptomatic attacks of FMF, and therefore a lack of intense acute-phase response during symptoms of abdominal pain, pleurisy and fever, etc., in an individual known to have FMF should suggest an alternative aetiology. Thirdly, the amount of acute-phase SAA production in asymptomatic patients with FMF is sufficient to account for their susceptibility to the development of AA amyloidosis, solving the enigma of why such an apparently intermittent disorder or, in the case of phenotype II FMF, an entirely subclinical process, should lead to this life-threatening complication. Substantial clinical experience has shown that regular prophylactic treatment with daily colchicine, at doses between 500 µg and 2.5 mg a day, inhibits attacks of FMF in two-thirds of patients [35], and prevents the development of AA amyloidosis in the vast majority of cases [36]. This treatment had been prescribed to all patients studied here, but the remarkable degree and intensity of acute-phase activity led us to question the participants’ compliance with the drug. Our suspicion was supported by experience that we have acquired though monitoring disease activity with monthly SAA measurements among FMF patients who have been under long-term follow-up in our centre in London, in whom we have observed SAA values of less than 10 mg/l on most occasions in most patients who assert that they are compliant with colchicine. On subsequent questioning after the present study had been completed, about half of the patients reported here admitted using colchicine either erratically or otherwise inappropriately. Since there is no risk of AA amyloidosis developing in individuals who do not have abnormal overproduction of SAA, frequent SAA measurements in patients with FMF may help to reinforce drug compliance, as well as providing objective evaluation of response and reassurance to the attending physician.

**Discussion**

This study has shown that substantial subclinical inflammation occurs widely and over prolonged periods in patients with FMF, indicating that the relatively infrequent clinically overt attacks represent the tip of the iceberg in this disorder. Although measurements of hs-CRP and SAA are well established to be the most sensitive and dynamic indicators of the acute-phase response, the magnitude of their elevation in active FMF, especially SAA, far exceeds values seen in most other chronic inflammatory diseases. The up-regulation of SAA and CRP production during health and intercurrent illness observed here over a prolonged time course in characterized MEFV heterozygotes confirms and extends previous observations on the phenotype of FMF carriers [33].

The up-regulation of SAA and CRP production during health and intercurrent illness observed here over a prolonged time course in characterized MEFV heterozygotes confirms and extends previous observations on the phenotype of FMF carriers [33].

![FIG. 1. Fortnightly SAA measurements, plotted on a logarithmic scale, in the eight FMF patients who remained completely without symptoms throughout the study period, showing substantial subclinical inflammatory activity. Thirteen per cent of all SAA values were greater than 50 mg/l. The median SAA value is indicated for each patient. Three patients were M694V/E148Q, including patient 7, who had very little evidence of inflammation. The other five patients all had two exon 10 mutations.](https://academic.oup.com/rheumatology/article-abstract/45/6/746/1785056/attachment/67f7f6f1275065172860656?Expires=7036642999&OSSAccessKeyId=JDvHAfS15jvGd15S6g1Q&Signature=0HxhjJ1QYFzso1fOoDc7UGsPcQX0C5)
Other notable findings in this study included the results of MEFV genotyping. The sequencing method used was relatively comprehensive but would not detect intronic mutations or indeed regulatory proteins. We identified pairs of mutations in more than 80% of patients with FMF, and single mutations in all but 5% of the remainder. The frequency of mutated MEFV alleles in the healthy control group was 22%, and pairs of mutations known to be associated with FMF were present in two of these individuals and in 12% of the patients’ apparently healthy relatives. In contrast, no mutations were identified in two FMF patients, emphasizing the limitations of genotyping in the diagnosis of this disorder and the need to use clinical criteria to make the diagnosis.

We have previously demonstrated that obligate carriers of FMF had increased levels of acute-phase reactants [37], and the combination of MEFV genotyping coupled with high-sensitivity acute-phase response measurements over several months reported here enabled us to confirm and further elucidate the pro-inflammatory phenotype among characterized heterozygous FMF carriers. Both basal and peak acute-phase protein concentrations were greater in MEFV heterozygotes than in wild-type controls, regardless of mutation. All endothermic animals mount an acute-phase response, suggesting that it may have survival value. Indeed, in an experimental mouse model, induction of the acute-phase response by a single sterile inflammatory stimulus markedly enhances resistance to otherwise lethal pyogenic bacterial infection [38]. Up-regulation of the acute-phase response among carriers of FMF may thus have benefited their innate host response and contributed to better resistance to infection, suggesting a hypothesis that the pyrin heterozygote state may have conferred a survival advantage during periods when early mortality from infectious disease was the major selection pressure. These advantages conferred by an up-regulated inflammatory response may be balanced in later life by a predisposition to atherosclerosis. However, despite widespread evidence that CRP is a moderate predictor of coronary heart disease [39], there is little published on the risk of heart disease in FMF. The only published paper suggests that colchicine-treated patients have no increased risk compared with the general population [40], and nothing is known yet on the incidence of cardiac disease among asymptomatic MEFV heterozygotes.

Acknowledgements
This work was supported in part by grants to P.N.H. from the Medical Research Council (UK) and The Wellcome Trust, and by NHS Research and Development Funds.

The authors have declared no conflicts of interest.

References


